Strategies to optimize the use of erythropoietin and iron therapy in oncology patients

Transfusion

Volumn 44, Issue 12 SUPPL., 2004, Pages

  Ford, Patricia A ^a   Mastoris, Jason ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE; HEMOGLOBIN; IRON; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; BONE PAIN; CANCER PATIENT; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; EDEMA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; EYELID EDEMA; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HEMOGLOBIN DETERMINATION; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONHUMAN; ONCOLOGY; PARESTHESIA; PLURIPOTENT STEM CELL; SIDE EFFECT; TASTE DISORDER; VOMITING;

ANEMIA; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; IRON; NEOPLASMS;

EID: 10444238652     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Eschbach JW, Downing MR, Egrie IC, et al. USA multicenter clinical trial with recombinant human erythropoietin (Amgen): results in hemodialysis patients. Contrib Nephrol 1989;76:160-5.
2. Eschbach JW, Kelly MR, Haley NR, et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321:158-63.
3. Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-8.
4. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990;322:1488-93.
5. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med 1992;117:739-48.
6. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000;97:10526-31.
7. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248:378-81.
8. Gorio A, Gokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A 2002;99: 9450-5.
9. Sirén AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001;98:4044-9.
10. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000 [Internet]. New York: National Kidney Foundation; 2001 [accessed 2004 May 6]. Available from: http://www.kidney.org/professionals/ kdoqi/guidelines_updates/doqi_uptoc.html#an
11. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999;33:464-70.
12. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616-34.
13. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998;25(Suppl 7):2-6.
14. Nowrousian MR, Kasper C, Oberhoff C, et al. Pathophysiology of cancer-related anemia. In: Smyth JF, Boogerts MA, Ehmer BRM, eds. rhErythropoietin in cancer supportive treatment. New York: Dekker; 1996:13-34.
15. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-92.
16. Hillman RS. Anemia. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill; 1998:334-9.
17. Bernaudin M, Bellail A, Marti HH, et al. Neurons and astrocytes express EPO mRNA. oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000;30:271-8.
18. Krantz SB. Erythropoietin. Blood 1991;77:419-34.
19. Henry DH. The evolving role of epoetin alfa in cancer therapy. Oncologist 2004;9:97-107.
20. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999;14(Suppl 2):22-8.
21. Gabrilove J. Overview: erythropoiesis, anemia, and the impact of erythropoietin. Semin Hematol 2000;37(Suppl 6):1-3.
22. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
23. Acs G, Xu X, Chu C, et al. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004;100:2376-86.
24. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911-8.
25. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-9.
26. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15: 1218-34.
27. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25.
28. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82.
29. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74.
30. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-9.
31. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126-34.
32. Patton J, Camp M, Kuzur M, et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy [abstract]. Blood 2002;100:16b-17b.
33. Henry DH, Bowers P, Romano MT, et al. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004;164:262-76.
34. Procrit® (epoetin alfa) prescribing information. Raritan (NJ): Ortho Biotech Products, L.P.; Revised 2002 Nov.
35. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
36. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(Suppl 1):3-10.
37. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76.
38. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
39. Glaspy JA, Jadeja JS, Justice G, et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003;97:1312-20.
40. Hesketh PJ, Arena F, Patel D, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 2004;100:859-68.
41. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
42. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
43. Wun T, Law L, Harvey D, et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514-20.
44. Zwillich T, Smith M. FDA eyes safety of popular anemia drugs. Available at: http://my.webmd.com/content/Article/ 86/99100.htm. Accessed June 29, 2004.
45. National Comprehensive Cancer Network. Cancer and Treatment-related Anemia Clinical Practice Guidelines in Oncology - v.2.2004. Available at: http://www.nccn.org/ physician_gls/f_guidelines.html. Accessed May 6, 2004.
46. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-20.
47. Mast AE, Blinder MA, Lu Q, et al. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 2002;99:1489-91.
48. Blake DR, Waterworth RF, Bacon PA. Assessment of iron stores in inflammation by assay of serum ferritin concentrations. Br Med J (Clin Res Ed) 1981;283: 1147-8.
49. Barron BA, Hoyer JD, Tefferi A. A bone marrow report of absent stainable iron is not diagnostic of iron deficiency. Ann Hematol 2001;80:166-9.
50. Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997;89:1052-7.
51. Henry DH. Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1998;3:275-8.
52. Ford P, Henry D, Mason B, et al. Iron status in anemic cancer patients [abstract]. Proc Am Soc Clin Oncol 1998;17:58a.
53. Wingard RL, Parker RA, Ismail N, et al. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995;25:433-9.
54. Patruta SI, Hǒrl WH. Iron and infection. Kidney Int 1999;69(suppl):S125-30.
55. Nissenson AR, Lindsay RM, Swan S, et al. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 1999;33:471-82.
56. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-7.
57. Barton JC, Barton EH, Bertoli LF, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000;109: 27-32.
58. Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002;61:1830-9.
59. Venofer® (iron sucrose injection, USP) prescribing information. Shirley (NY): American Regent, Inc.; 2003.
60. Charytan C, Schwenk MH, Al-Saloum MM, et al. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract 2004;96: c63-6.
61. Kosch M, Bahner U, Bettger H, et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer®) vs iron gluconate (Ferrlecit®) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001;16:1239-44.